BioWorld MedTech

Jan. 29, 2016

Engaged Under Pressure: Heartware nixes Valtech deal citing 'different set of circumstances'

Just three weeks after vehemently defending its proposed acquisition of Valtech Cardio Ltd. (Yehuda, Israel), Heartware International Inc. (Framingham, Mass.) nixed the stock-based deal, which was valued at $929 million and announced in September. Read More

Inside the Beltway: CMS advises Theranos Medicare privileges at risk after inspection

Beat Target in Down Market: Vexim raises $11 million to challenge spine market in the US

Path to care paved with good intentions: Boston Sci, Accenture develop Advantics Care Pathway solution for HF patients

Financings: Neurotrack raises $6.5 million

Court Report: Oral argument calendared for Retractable Technologies, BD case

Product briefs

People in Places

MDD's Orthopedics Extra

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...